Description: Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" – nimble and focused biopharmaceutical and health technology companies.
Home Page: roivant.com
ROIV Technical Analysis
11-12 St. James’s Square
London,
SW1Y 4LB
United Kingdom
Phone:
44 2074 003 347
Officers
| Name | Title |
|---|---|
| Mr. Vivek Ramaswamy | Founder & Chairman |
| Mr. Matthew Gline | CEO & Director |
| Dr. Eric Venker M.D., Pharm.D. | Pres & COO |
| Dr. Mayukh Sukhatme M.D. | Pres & Chief Investment Officer |
| Mr. Richard Pulik | Chief Financial Officer |
| Ms. Rakhi Kumar | Chief Accounting Officer |
| Dr. Huafeng Xu Ph.D. | Chief Technology Officer |
| Mr. Josh Chen | Gen. Counsel |
| Ms. Kelly Graff | Head of People |
| Ms. Marianne L. Romeo | Head of Global Transactions & Risk Management |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.3753 |
| Price-to-Sales TTM: | 104.1739 |
| IPO Date: | 2021-10-01 |
| Fiscal Year End: | March |
| Full Time Employees: | 863 |